Track topics on Twitter Track topics that are important to you
SAN DIEGO, July 31, 2017 /PRNewswire/ -- Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, today announced that it supports the decision of the Senate Appropriations Committee to approve renewal of the Rohrabacher-Farr amendment, which prohibits the Justice Department from spending funds to interfere with the implementation of state medical cannabis laws. The amendment was enacted in 2014 and has been renewed each year since then.
As America took its latest step in protecting its state-sanctioned medical cannabis programs, just south of the border a group of renowned doctors met to discuss the therapeutic benefits of cannabis. During the LX Annual Meeting and National Congress of the Mexican Chapter of the International League Against Epilepsy in Tijuana, Mexico, Medical Marijuana Inc. subsidiary HempMeds® Mexico provided information about cannabinoid products for the treatment of neurodegenerative conditions, such as epilepsy. The event shared results obtained by Mexican doctors using the first cannabis based treatment approved in Mexico that is the Company's Real Scientific Hemp Oil-X™ (RSHO-X™).
"We are encouraged by the United States Senate Appropriations Committee's decision to protect the wellbeing of millions of patients in states that have taken the necessary steps to create a legal cannabis program by renewing this amendment," said Medical Marijuana Inc. CEO Dr. Stuart Titus. "With 60% of US States now with medical cannabis laws in place, it would be absurd not to ensure the success of these fully state-sanctioned cannabis programs."
In the United States, a total of 30 states, the District of Columbia, Guam and Puerto Rico now allow for comprehensive public medical cannabis programs. Sixteen states allow the use of low THC, high cannabidiol (CBD).
About Medical Marijuana, Inc.
We are a company of firsts®. Our mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value. For details on Medical Marijuana, Inc.'s portfolio and investment companies, visit www.medicalmarijuanainc.com.
FORWARD-LOOKING DISCLAIMER AND DISCLOSURES
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.
The statements in this press release have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. The Company does not sell or distribute any products that are in violation of the United States Controlled Substances Act. The Company does sell and distribute hemp-based products.
SOURCE Medical Marijuana, Inc.NEXT ARTICLE
Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...
Epilepsy is defined as a disorder of brain function characterized by recurrent seizures that have a sudden onset. (Oxford Medical Dictionary). A seizure is caused by a sudden burst of excess electrical activity in the brain, causing a tempora...